Form 4: SOPHIA GENETICS CTO Sells Shares for Tax Withholding

SOPHIA GENETICS SA's Chief Technology Officer, Abhimanyu Verma, sold 6,944 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 6,944 ordinary shares on June 25, 2026.
• The sale was conducted to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• These transactions were executed as part of a pre-established Rule 10b5-1(c) trading plan.
• The weighted average sale price was $5.5054, with individual sales ranging from $5.31 to $5.69.
• Following the sale, Verma beneficially owns 197,456 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves a sale of shares by a key executive, it is a routine transaction for tax purposes under a pre-defined plan, not indicative of a negative view on the company's prospects.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, indicating pre-planned and potentially less discretionary activity.
• The transaction was to satisfy tax withholding obligations, a common and expected event for executives with equity awards.

Negatives

• A reduction in the reporting person's direct shareholding.

Risks

• While executed under a 10b5-1 plan, any significant sale by a key executive could be perceived negatively by the market.
• The need to sell shares for tax withholding may indicate a liquidity concern for the executive, though this is a standard practice.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Abhimanyu Verma, CTO of SOPHiA GENETICS SA, aligns with best practices for executives managing their equity holdings and potential tax liabilities in a compliant manner.

Stakeholder Impact

• Shareholders: The sale is a minor reduction in the CTO's holdings, executed under a plan, and is unlikely to have a significant impact on share price or overall shareholder value.
• Employees: No direct impact on employees is indicated by this transaction.
• Creditors: No impact on creditors.
• Suppliers: No impact on suppliers.

Next Steps

• The reporting person will continue to hold the remaining 197,456 ordinary shares.
• Further transactions, if any, will be reported on subsequent SEC filings.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Tax Withholding, Rule 10b5-1, SOPHIA GENETICS SA, Abhimanyu Verma, Chief Technology Officer, Ordinary Shares, Restricted Stock Units